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 Abstract 
Tobacco use though cigarette smoking is the leading preventable cause of death in the 
developed world. The pharmacological effect of nicotine plays a crucial role in tobacco 
addiction. Nicotine dependence has a huge impact on global health and although several 
medications are available, including a wide range of nicotine-replacement therapies 
(NRTs), bupropion, and recently approved nicotinic receptor partial agonist varenicline, 
at best only about a fifth of smokers are able to maintain long-term (12 months) 
abstinence with any of these approaches. Thus, there is a need to identify more effective 
pharmacotherapy to aid smokers in maintaining long-term abstinence. Converging 
evidence from animal and human cognitive neurosciences studies indicate that cognitive 
functions, particularly inhibitory cognitive control, are linked closely to addictive 
behaviours. Drug addiction has been described as a disease of the brain reward system 
wherein drugs activate the neuronal circuitry involved in reward and memory. Because 
of the effect of cholinergic systems on reward and drug self-administration, the 
prevalence of acetylcholine (ACh) within the striatum, and the involvement of ACh in 
higher cognitive processes, ACh may play an important role in the addictive processes 
underlying nicotine dependence. These diverse functions are mediated by nicotinic 
(nAChRs) and muscarinic (mAChRs) receptors. Cholinergic neurons are either 
projecting neurons, terminating diffusely in the brain, or interneurons, which are located 
mainly in striatum and nucleus accumbens (NA). While cholinergic projection neurons 
are critical in cognitive function, cholinergic interneurons integrate cortical and 
subcortical information related to reward.  
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The cholinergic system interacts with the dopaminergic reward system at three levels: 
ventral tegmental area (VTA), NA and prefrontal cortex (PFC). In the VTA, both 
nAChRs and mAChRs stimulate the dopaminergic system. In the NA, cholinergic 
interneurons inhibit the dopaminergic system and integrate the cortical and subcortical 
information related to reward. In the PFC, the cholinergic system contributes to the 
cognitive control of addictive processes, although the neurobiological mechanism 
remains to be elucidate.  
Acetylcholinesterase inhibitors (AChE-Is) have been developed and introduced into 
clinical practice for the treatment of cognitive deficits in neurological and psychiatric 
disorders. Their therapeutic action is mediated through increase extracellular 
acetylcholine (ACh) levels as a result of the inhibition of acetylcholinesterase (AChE), 
the enzyme that cleaves ACh into choline and an acetyl-moiety. The two AChE-Is 
galantamine and physostigmine exhibit allosteric potentiation ligand properties (APL) 
on nAChRs. Tacrine, the first AChE-I introduced into clinical practice, does not act as 
an APL at nAChRs.  
The aim of this research is to investigate the role of ACh in nicotine dependence and 
how ACh modulates the mesocorticolimbic dopamine pathway. To address this question 
AChE-Is have been used as pharmacological tools to elevate the ACh level in the brain 
and the experimental paradigms applied in this research for investigating the addictive 
properties of nicotine were the drug discrimination (DD), self-administration (S/A) and 
reinstatement models. All these paradigms are operant conditioning models that mimic 
different phenomena of addictive behaviour. In particular, S/A directly measures the 
reinforcing and rewarding effects of drugs; drug discrimination provides information 
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regarding the interoceptive stimulus effect that a drug can exert and the reinstatement 
model corresponds to the human behaviour of relapse. 
Galantamine, physostigmine and tacrine were initially tested in the drug discrimination 
model in rats trained to discriminate nicotine from saline. Galantamine and 
physostigmine partially generalized for nicotine discriminative stimulus; tacrine did not 
generalize to nicotine except for the highest tested dose. Physostigmine and tacrine were 
then selected to be tested in the nicotine self-administration model. Physostigmine and 
tacrine pre-treatment did not induce any significant changes on the number of nicotine 
infusions. Finally, tacrine was chosen as a test compound to be investigated in the 
extinction and relapse model. Tacrine administered chronically did not exert any effect 
either on extinction of nicotine self-administration behaviour, or on drug cues or 
nicotine priming reinstatement. 
The present results from animal studies show a lack of effect of AChE-Is on different 
aspects of nicotine addiction behaviour, but a number of limitations need to be taken 
into account. These findings also need to be integrated with clinical data available on 
this pharmacological class of compounds in order to create a more comprehensive 
picture for the potential use of AChE-Is as treatment for nicotine addiction. 
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 1. Introduction 
 
Cigarette smoking and other forms of tobacco use impose a large and growing global 
public health burden. Worldwide, tobacco use is estimated to kill about 5 million people 
annually, accounting for 1 in every 5 male deaths and 1 in 20 female deaths of those 
over age 30. On current smoking patterns, annual tobacco deaths will rise to 10 million 
by 2030 (Jha et al., 2006). Treatment for smoking cessation includes diverse methods 
from simple medical advice to pharmacotherapy. The powerful addictive properties of 
nicotine create a huge hurdle, even for those with strong desire to quit. Approximately 
80% of smokers who attempt to quit on their own relapse within the first month of 
abstinence, and only 3-5% remain abstinent at 6 months (Hughes et al., 2004). The 
pharmacologic effect of nicotine plays a crucial role in tobacco addiction, and therefore 
pharmacotherapy is important to address this component of tobacco dependence in 
order to improve success rate (Benowitz, 2010). Present clinical practice guidelines 
categorise pharmacotherapy for the treatment of tobacco dependence into first-line 
[nicotine replacement therapy (NRT), bupropion and varenicline] and second-line 
medications (including nortriptyline and clonidine), although latter medications are used 
only in combination (Pelosa and Benowitz, 2011). 
Dysfunction of cholinergic transmission and muscarinic and nicotinic acetylcholine 
(ACh) receptors have been associated with several psychiatric disorders characterized 
by gradual loss of cognitive functions (Pepeu and Giovannini, 2004) including 
Alzheimer’s Disease (AD), schizophrenia (Breese et al., 2000; Freedman et al., 2000), 
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and drug addiction (Williams and Adinoff, 2008). An analogous, if not homologous, 
mechanism may be critical in modulating the acute and chronic effects of drugs of 
abuse. Dopaminergic fronto-cortical dysfunction has been shown to result from 
neuroadaptation at different modulatory systems, including the cholinergic system 
(Williams and Adinoff, 2008). As a result, long-lasting cognitive impairment may 
accompany detoxification and may also be a determinant factor for relapse to drug use 
(Block et al., 2002). Therefore, cognitive impairment (Rogers and Robbins, 2001), 
particularly the control of impulsivity and decision making has been recommended as 
a therapeutic target for drug addiction (Vocci et al., 2005). 
The role of nicotinic ACh receptors (nAChRs) in cognitive processes has been widely 
demonstrated in laboratory animals, healthy volunteers and neuropsychiatric patients 
(Levin et al., 2006).  nAChRs are expressed in brain areas, such as neocortex and 
ascending modulatory pathways, involved in cognitive, affective and motivational 
processes. nAChRs mediate the effects of ACh release at cholinergic nerve terminals 
and also modulate the effects of several other neurotransmitter systems (Mansvelder et 
al., 2006; Albuquerque et al., 2009). The nAChRs agonist nicotine has cognitive-
enhancing and reinforcing properties in animal and human laboratory studies, as well 
in smokers and neuropsychiatric patients (Levin et al., 2006). Therefore, according to 
the widely distributed pattern of nAChRs in the brain and the addictive effects of 
nicotine, it is agreed that nAChRs may play an important role in mediating the 
cholinergic effects of not only tobacco, but also, more broadly, drug addiction. The 
ubiquitous brain projection of cholinergic pathways, the low temporal resolution of 
neurochemical assessments, the lack of selective (at receptor and/or anatomical level) 
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and feasible (devoid of side-effects) pharmacological tools are some of the critical 
factors that limited research advances in this field compared to others. 
Acetylcholinesterase Inhibitors (AChE-Is) have been developed and introduced in the 
clinical practice for the treatment of neurological diseases (Cummings, 2003), and 
psychiatric disorders characterized by cognitive deficits. Cholinomimetic drugs 
(Buccafusco 2004; Chiamulera and Fumagalli, 2007), including AChE-Is, 
significantly improved clinical endpoints such as sustained attention, working 
memory, visual detection, verbal fluency, and quality of life in psychiatric patients 
(Kirrane et al., 2001; MacEwan et al., 2001; Lenzi et al., 2003; Chouinard et al., 
2007). Both, the proposed therapeutic effect (pro-cognitive), and the mechanism of 
action (cholinomimetic) strongly support studies with AChE-Is for the treatment of 
drug addiction. Reversible AChE-Is slow down ACh metabolism and increase 
extracellular ACh levels by inhibiting ACh-esterase (AChE), the enzyme which 
cleaves ACh into choline and an acetyl- moiety. AChE-Is currently approved for the 
treatment of dementia are; tacrine, donezepil, rivastigmine and galantamine (Ritchie et 
al., 2004). Galantamine is an AChE-I currently approved for the treatment of 
dementia, whereas physostigmine and tacrine are not widely used in clinic.  However, 
physostigmine and tacrine are valuable tools to investigate the effects of increased 
synaptic ACh and its subsequent binding to nAChRs and muscarinic (mAChRs) 
receptors (Clarke and Pert 1985; Calabresi et al., 1989). Galantamine and 
physostigmine have been shown to exert a dual mechanism of action: selective 
competitive inhibition of AChE and positive allosteric modulator (APL) properties on 
nAChR response (Storch et al., 1995; Maelicke and Albuquerque, 2000; Samochocki 
6 
 
et al., 2003; Svobodova et al., 2005). APLs enhance the probability of agonist-
mediated channel opening, stabilise the open-channel state and decrease the rate of 
desensitization of nAChRs (Schrattenholz et al., 1996). Although the mode of action 
by which galantamine and physostigmine enhance the sensitivity of nAChRs to 
agonists is not yet fully understood, it has been shown that both drugs directly interact 
with nAChRs, at sites close to, but distinct from, the ACh and nicotine binding sites. 
Potential binding sites have been located on the α4β2 and α7 nAChRs subunits 
(Texido’ et al., 2005; Militante et al., 2008; Luttmann et al., 2009). Unlike 
galantamine and physostigmine, tacrine, the first AChE-I introduced in the clinical 
practice, does not act as an APL at nAChRs (Davis and Powchick, 1995). 
 
1.1. Neuroanatomical and neurochemical interactions between 
cholinergic and dopaminergic systems 
 
Cholinergic neurons are distributed through the central nervous system (CNS) and 
provide diffuse and sparse innervation to broad areas of the brain (Woolf, 1991). In 
particular, cholinergic neurons located in mesopontine nuclei (MN) and in striatum 
innervate the prefrontal cerebral cortex (PFC), amygdala, thalamus, ventral tegmental 
area (VTA), substantia nigra (SN) and hippocampus (Figure 1).  
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 Figure 1. Picture taken from William & Adinoff (2008).  The primary sources of cholinergic input are 
(1) the mesopontine nuclei, which provide ACh innervations to ventral tegmental area (VTA), 
substantia nigra (SN) and thalamus, (2) the nucleus basalis of Meynert (NBM) which provide ACh 
input to cerebral cortex and amygadala, and (3) the medial septal-diagonal band of Broca which 
provides ACh input to hippocampus. Striatal ACh interneurons are influenced by dopamine (DA) 
receptors D1 and D2. Stiatal muscarinic ACh interneurons primarly consist of M1, M2 and M4; M1 is 
post-synaptic (Mpost) and excitatory, whereas M2 and M4 are pre-synaptic (Mpre) and inhibitory. These 
interneurons synapse with γ-aminobutyric acid (GABA) medium spiny output neurons (MSNs). The 
ventral striatum  projects output neurons to he ventral palladium (VP) of the globus pallidus (GP) and 
,in turn, to the mediodorsal (MD) nucleus of the thalamus. The GP further projects, through GABAergic 
neurons, to the MD nucleus. Glutamatergic neurons from the MD project to prefrontal cortex (PFC).  
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These brain areas are known to be the target of drugs of abuse and of addiction-related 
processes such as drug self-administration (S/A) and drug-seeking behaviours (Box 1).  
 
 
Neuroanatomical studies on cholinergic receptor (AChRs) distribution strongly 
implicate muscarinic and nicotinic receptors as mediators of the reinforcing effects of 
drugs. mAChRs are G-protein-coupled receptors that mediate slow responses and 
include five subtypes (M1–M5). mAChRs M1, M4 and M5 are mainly localised in 
striatum, cortex and hippocampus. nAChRs are ligand-gated ion channels that open, 
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upon binding with ACh, to allow fast diffusion of cations (Albuquerque, 2009). 
Neuronal nicotinic receptors are either heteromeric (e.g. α4β2) or homomeric (e.g. α7) 
transmembrane proteins formed by different types of α (α2-α10) and β (β2-β4) subunit 
combinations (α2-α6, α10, and β2-β4). nAChRs receptors α4β2 and α7 subtypes are 
expressed in striatal and mesolimbic dopaminergic neurons (Clarke and Pert, 1985). 
While mAChRs are expressed at high levels in both striatal and mesolimbic 
dopaminergic neurons, nAChRs are expressed at high level on both dopamine (DA) 
and GABA neurons in the VTA, and on both DA and GABA terminals in the striatum, 
but at low level on striatal cell bodies. Within the ventral striatum, the NA core is 
thought to process reinforced behaviours (Pontieri et al., 1995), whereas the NA shell 
processes and regulates reflexive autonomic and motor responses to drugs of abuse 
(Groenewegen et al., 1996). The role of the dorsal striatum in habit learning which 
then mediates drug-seeking behaviours after response acquisition is well established. 
Striatal cholinergic interneurons receive dopaminergic projections from the VTA and 
SN (Everitt and Robbins, 2005) and express both DA D1 and D2 receptors. Based on 
this, several studies have evaluated the effects of direct or indirect DA stimulation on 
ACh neurotransmission. For example, stimulation of D1 receptors increased, whereas 
activation of D2 receptors decreased, striatal ACh release (Consolo et al., 1999; 
Alcantara et al., 2003). Morphine, cocaine or food all altered cholinergic transmission 
in the NA (Hurd et al., 1990; Rada et al., 1996; Smith et al., 2004) through both D1 
and D2 receptors, but also through mAChRs and nAChRs (Imperato et al., 19931; 
Imperato et al., 19932; Consolo et al., 1999; Pratt et al., 2004). It appears that, at least 
under acute conditions, the reinforcing effects of drugs are associated with an 
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increased striatal ACh release. Other studies have explored the effects of AChRs 
modulation on DA output. For example, intra-VTA administration of carbachol or 
oxotremorine (non-selective mAChRs agonists) increased DA concentrations in NA 
and VTA (Blaha and Winn, 1993; Blaha et al., 1996; Gronier et al., 2000). 
Furthermore, atropine (mAChRs antagonist) administered by reverse microdialysis 
into NA reduced remifentanil reinforcing effects (Crespo et al., 2006). Furthermore, 
when atropine was infused intravenously it inhibited nicotine-induced DA release in 
the NA (Sziráki et al., 1998). The same effect was blocked by the nAChRs antagonist 
mecamylamine, suggesting that nicotine-induced DA release involves by both 
mAChRs and nAChRs (Table 1).  
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VTAa 
 
 
NAb 
 
BLAc 
 
References 
ACh 
 
↑ ICSS    [Redgrave] 
Atropine 
 
↓ ICSS  
= Nicotine S/A 
↓ Nicotine-induced 
DA 
↓ Remifentanil 
reinforcement 
 [Yeomans ;Corrigall 
1994, 2002 ; Sziraki; 
Crespo]  
 
Carbachol 
 
 
↑ CPP  
↑ ICSS  
 
↑  DA 
  
[Ikemoto;Yeomans;Blaha] 
 
Oxotremorine ↑  DA ↑  DA ↑ extinction 
amphetamine-
induced CPP  
[Schroeder; Gronier] 
 
Neostigmine 
 
↑ ICSS 
↓ Nicotine S/A 
↑  DA  [Yeomans;Corrigall 2002;
Blaha] 
 
 
Donepezil 
 
 ↓ Cocaine- and 
morphine-induced 
CPP  
↓methamphetamine-
induced 
reinstatement 
  
[Hikida; Hiranita] 
 
Pysostigmine 
 
 
↑ Cue-induced 
heroin 
reinstatement  
 
↓ Cue-induced 
heroin reinstatement  
  
[Zhou] 
 
Scopolamine 
 
 
= Nicotine S/A 
 
  
↓ Cue-
induced 
cocaine 
reinstatement  
 
[Corrigall 2002; See] 
 
Mecamylamine 
 
 ↓ Nicotine-induced 
DA 
↓ Remifentanil 
reinforcement 
  
[Sziraki; Crespo] 
 
 
Table 1. Summary of the neurochemical and behavioural effects of cholinergic agonists and antagonists 
microinjected into the ventral tegmental area (VTA), nucleus accumbens (NA) or basolateral amygdale 
(BLA). ↓ decrease of primary dependent variable; = no significant change; ↑ increase of primary 
dependent variable. 
 
Overall, the literature indicates that mAChRs and nAChRs agonists enhance, whereas 
antagonists reduce brain DA release. Based on these studies it is predicted that 
cholinergic agonists would enhance, whereas cholinergic antagonists would decrease 
the reinforcing effects of drugs. However, selective brain lesions and direct 
administration of cholinergic agonists into the brain did not always produce consistent 
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results in behavioural assays.  For example, carbachol and neostigmine (an AChE-I) 
have been shown to induce conditioned place preference (CPP) and intracranial self-
stimulation (ICSS; Box 2) when they were injected into the posterior portion of the 
VTA (Yeomans et al., 1985; Ikemoto and Wise, 2002). Similarly, ACh potentiated 
ICSS (Redgrave and Horrell, 1976), whereas atropine shifted ICSS frequency curves 
to the right, i.e. increase the hedonic threshold, in rats (Yeomans and Baptista, 1997). 
The AChE-I physostigmine microinfused intra-VTA increased reinstatement of 
heroin-seeking induced by conditioned cues (Zhou et al., 2007), but decreased it when 
injected intra-NA. In a separate study, neostigmine microinjected into the VTA 
reduced nicotine S/A (Corrigall et al., 2002) (Table 1). Lesions of the 
peduncolopontine tegmental nucleus (PPTg) in the MN inhibited morphine- and 
amphetamine-induced CPP (Bechara and van der Kooy, 1989; Olmstead & Franklin, 
1993). Intravenous nicotine S/A increased when the posterior portion of the PPTg was 
selectively lesioned with ibotenic acid (Alderson et al., 2006). In contrast, nicotine S/A 
was decreased by PPTg lesions (Lança et al., 2000), whereas it was unchanged after 
intra-VTA administration of atropine and scopolamine (Corrigall et al., 2002; 
Corrigall et al., 1994). It is important to recognize that several factors may have 
contributed to these inconsistent results, including the use of different schedules of 
reinforcement (Box 1), the type of procedure (CPP vs. self-administration), the 
assessment of the reinforcing effects in the acquisition phase in some studies and in 
the maintenance phase in others, as well as the lack of an accurate knowledge of the 
dose-effect relationship for intravenous S/A, and specificity in the lesion experiments. 
Collectively, the literature indicates that cholinergic agonists microinjected into the 
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VTA increased the reinforcing effects of drugs of abuse and enhanced DA release in 
the NA, whereas when they were microinjected into the NA they had opposite effects. 
These data pose some questions on the efficacy of cholinergic agonists on drug 
reinforcement after systemic administration and suggest that a systematic approach 
with AChE-Is could provide some answers. 
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 1.2. Acetylcholinesterase inhibitors as experimental tools to increase 
ACh levels 
 
Inhibition of AChE increases the synaptic concentration of ACh, thereby enhancing 
and prolonging the action of ACh on both mAChRs and nAChRs. The AChE-Is 
currently approved for the treatment of dementia are tacrine, donezepil, rivastigmine 
and galantamine (Ritchie et al., 2004). Although the primary mechanism of action of 
these drugs is inhibition of AChE, they differ in potency and selectivity, i.e. inhibition 
of AChE vs. butyrylcholinesterase (BChE). A significant increase in brain ACh can 
occur not only after AChE inhibition, but also after BChE inhibition as shown under 
some conditions (Cerbai et al., 2007). For example, tacrine, a reversible AChE-I, is 
slightly more potent for BChE than AChE (Davis and Powchick, 1995). On the other 
side of the specificity profile is donepezil highly selective for AChE (Villarroya et al., 
2004). Physostigmine and galantamine, but not donepezil and rivastigmine, also act as 
nAChRs APL (Samochocki et al., 2003). Physostigmine and galantamine bind to a site 
distinct from the ACh-binding site on nAChRs subunits.  This site is insensitive to 
blockade by competitive nAChR antagonists and has been detected even when the 
receptors were desensitized by large concentrations of agonists (Pereira et al., 1994). 
Others have shown that chronic treatment with AChE-Is increases nAChRs expression 
in rodents (Bhat et al., 1990). For example, chronic administration of donepezil, 
rivastigmine and galantamine increases non-α7 nAChR expression in rat 
hippocampus, and both non-α7 and α7 nAChR expression in cerebral cortex (Reid & 
Sabbagh, 2008; Takada-Takatori et al., 2008). In general, in vitro and in vivo data 
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have indicated that AChE-Is may increase nAChRs expression by increasing synaptic 
ACh levels, and not by direct agonist activity at the nAChRs (Kume et al., 2005). 
Collectively, these data indicate that inhibition of AChE (primary mechanism) may be 
slightly different across AChE-Is in terms of potency and selectivity. Moreover, 
further pharmacological differences may arise from secondary mechanisms such as 
nAChRs APL properties and receptor up-regulation complicating the pharmacological 
profile of the AChE-Is. Thus, the use of AChE-Is as experimental tools for 
understanding the mechanisms underlying the cholinergic component of drug 
reinforcement should be considered only after choice of route of administration 
(intracranial or systemic) and of their secondary pharmacological effects, in particular 
alternative mechanism on nAChRs, are taken into account. 
 
1.3. Preclinical effects of acetylcholinesterase inhibitors on drug 
reinforcement 
 
Several studies have shown that AChE-Is have biological effects in animal models of 
drug reinforcement and that these effects depend on route of administration. Direct 
brain administration of AChE-Is resulted in differential effects depending on the 
neuroanatomical site of injection (Table 1). Behavioural studies combined with 
cholinergic cell ablation, reported that elimination of cholinergic cell in the NA 
markedly enhances sensitivity to cocaine in both acute and long-lasting behavioural 
changes associated with cocaine addiction (Hikida et al., 2001). This study revealed 
that ACh is released from cholinergic interneurons within the NA and acts concertedly 
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but oppositely to dopamine on the NA neuronal circuit and that the elimination of 
cholinergic neurons in NA increases behavioural effects of cocaine rewarding. In a 
subsequent experiment, Hikida et al.(2003), showed that ablation of the NA 
cholinergic neurons enhanced not only the sensitivity to morphine in CPP but also 
negative reinforcement of morphine withdrawal in conditioned place aversion. 
Remarkably, the AChE-I donepezil, suppressed both cocaine- and morphine-induced 
CPP and blocked the induction and persistence of cocaine-evoked hyperlocomotion. 
Importantly, this inhibition was abolished by ablation of the NA cholinergic neurons. 
These results demonstrate that centrally active AChE-Is prevent long-lasting 
behavioural abnormalities associated with cocaine and morphine addictions by 
potentiating the action of ACh released from NA cholinergic neurons (Hikida et al., 
2003). Hiranita et al., (2006) demonstrated that reinstatement of methamphetamine 
(MAP) -seeking behaviour is mediated by ACh and can be attenuated by donepezil. In 
fact systemic nicotine and donepezil administration attenuated MAP-associated cues 
and MAP-priming reinstatement. The AChE-Is physostigmine, produced dose-
dependent inhibition of cue-induced reinstatement of heroin-seeking behaviour (Zhou 
et al., 2007). In the same study Zhou et al., demonstrated that microinjection of 
physostigmine in the NA prior to presenting conditioned cues inhibited the 
reinstatement of heroin-seeking. In contrast, microinjection of physostigmine in the 
VTA augmented the reinstatement induced by conditioned cues and extinction 
responding. Inactivation of either NA or VTA by tetradotoxine microinjection blocked 
both extinction and cue-induced reinstatement. These data demonstrate that 
cholinergic transmission influences heroin self-administration and reinstatement. 
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Moreover, cue-induced reinstatement was inhibit by physostigmine in the NA and 
potentiated by cholinergic stimulation in the VTA. 
In addition, selective cholinergic lesions (i.e. induced by an immunotoxin) of NA 
neurons prevented the inhibitory effects of donepezil on morphine-induced CPP 
(Kaneko et al., 2000), suggesting that the NA was the site of action of donepezil. 
Unfortunately, these studies did not evaluate the effects of donepezil in the VTA. Such 
a study would have clarified the differential responses generated when an AChE-I is 
microinjected into the VTA compared to the NA. More recently, it has been shown 
that, in addition to VTA and NA, the BLA is also critical for conditioned memory 
formation. For example, when scopolamine was infused into the BLA it dose-
dependently disrupted cocaine-induced reinstatement (See, 2005). Furthermore, 
oxotremorine facilitated extinction of amphetamine-induced CPP (Schroeder & 
Packard, 2004). Taken together, these results indicate that increase of ACh 
neurotransmission in the NA and BLA decreases the reinforcing effects of drugs.  
When AChE-Is were administered systemically (Table 2) the effects were similar to 
those obtained after microinjection into the NA. For example, systemic administration 
of physostigmine produced dose-dependent inhibition of cue-induced heroin-seeking 
behaviour (Zhou et al., 2007). Furthermore, systemic administration of physostigmine 
reduced cocaine S/A in rhesus monkeys (De La Garza & Johanson, 1982). Tacrine 
inhibited cocaine S/A in rats (Grasing et al., 2008) and systemic administration of 
donepezil reduced morphine- and cocaine-induced CPP as well as hyperlocomotor 
activity in mice (Hikida et al., 2003). Systemic administration of galantamine and 
donepezil also blocked cocaine-induced motor sensitization, suggesting a potential 
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role of AChE-Is in neuroadaptation induced by psychostimulants. Furthermore, 
intraperitoneal administration of donepezil attenuated cue- and methamphetamine-
induced reinstatement in rats (Hiranita et al., 2006). Interestingly, these effects were 
blocked by mecamylamine and not by scopolamine, suggesting that they were 
mediated nAChRs. In contrast, others have demonstrated that systemic administration 
of physostigmine reduced heroin S/A and seeking behaviour in rats and these effects 
were blocked by scopolamine suggesting that were mediated by mAChRs (Zhou et al., 
2007).  
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Table 2. Summary of systemically administered AChE-Is effects on preclinical (primary dependent 
variables in laboratory animal models) and clinical addiction (clinical endpoints) measures. a Conditioned 
Place Preference in mice; b Locomotor activity or motor sensitization in mice or rats; c Drug S/A; d Cue- 
or drug priming –induced drug seeking relapse; e Psychological subjective measures such as craving, 
anxiety, etc.; f Behavioural objective measures such as relapse or consumption. ↓ Decrease of primary 
dependent variable or clinical endpoint; = No significant change. 
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In general, systemic administration of AChE-Is decreased the reinforcing effects of 
drugs although the exact mechanism (i.e. nAChRs vs. mAChRs) by which this 
occurred has not been completely clarified. Taken together, the data published so far 
indicate that the ability of systemically administered AChE–Is to reduce the 
reinforcing effects of drugs is consistent with a potentiation of cholinergic 
neurotransmission in the NA. Although, additional preclinical studies should be 
conducted to evaluate differences related to the different routes of AChE-Is 
administration (i.e. intra-NA, -VTA and systemic administration), these data indicate 
that systemic administration of AChE-Is inhibits the reinforcing effects of drugs of 
abuse in laboratory animals. Thus, these preclinical data strongly suggest a potential 
clinical utility of AChE-Is for the treatment of drug addiction.  
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 1.4. Aim 
 
This research originated from the experimental evidence that ACh contributes to 
homeostatic regulation in the mesolimbic dopamingergic pathway, which has a 
fundamental role in behavioural adaptations that occurs with repeated administration 
of drug of abuse, including nicotine.  
The aim of this research is to investigate the role of ACh in nicotine dependence, and 
how ACh modulates the mesocorticolimbic dopamine pathway. To address this 
question AChE-Is have been used as pharmacological tools to elevate the ACh level in 
the brain. The recent availability of neurochemical ACh measurements at a sub-second 
temporal scale (Giuliano et al., 2008) is not yet widely used, thus, behaviourally 
correlated ACh changes have at best, 10-15 minutes temporal resolution as assessed 
by microdialysis methods.  
The experimental paradigms applied in this research for investigating the addictive 
properties of nicotine were the drug discrimination, self-administration and 
reinstatement models. All these paradigms are operant conditioning models. The term 
operant conditioning describes one type of associative learning in which there is a 
contingency between a behaviour and the presentation of a biologically significant 
event (e.g. reinforcer). A positive reinforcement (e.g. nicotine administration) occurs 
when a behaviour (lever press) is followed by a stimulus which is appetitive or 
rewarding, increasing the frequency of that behaviour. Some psychoactive drugs 
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including nicotine are abused because of their ability to act as reinforcers. As a 
consequence behavioural patterns (such as drug seeking/drug taking behaviour) are 
promoted that ensure further drug consumption. Addiction cannot be modelled in 
animals, at least a whole, however different procedures of operant behaviour can be 
applied as rodent analogues of addiction’s major elements including discriminative 
effect, drug seeking and relapse (Ator and Griffiths, 2003; Sanchis-Segura & 
Spanagel, 2006). The most common apparatus used in conducting an operant task is 
the so-called “Skinner box” (Figure 2). 
 
 
Figure 2. Skinner box 
22 
 
The potential interpretative outcome is to integrate circumstantial data coming from 
scientific evidence in animal models and clinical data into a comprehensive picture for 
the potential use of AChE-Is in nicotine addiction. In particular, last-cognitive 
impairment may act as a determinant factor for relapse to drug use (Block et al., 2002), 
and these findings suggest the importance of studying the potential therapeutic value 
of ‘cognitive enhancers’ for prevention of relapse 
 
1.5. Behavioural paradigms 
 
The models applied in this research, are based on the experimental paradigm of operant 
conditioning. The two major experimental paradigms are the drug discrimination and 
the drug self-administration, respectively for the assessment of discriminative and 
reinforcing stimulus properties. In laboratory animals, conditioning tests take place 
inside a Skinner box (Figure 2), within a sound-insulated cubicle, and provided with 
levers, cue lights and speakers in order to set different experimental contingencies. A 
module-based system interfaces and computers with properly compiled software 
independently control all boxes. Briefly, experimental subjects are trained to receive a 
reward if they exhibit a specific behavioural response. The reward increases the 
probability of responding occurrence, therefore acting as a ‘reinforcer’. This mechanism 
is physiological and it sustains motivated behaviours for seeking and obtaining natural 
rewards such as food, water, sex, etc. Drugs of abuse may act as primary reinforcers, as 
it is observed in addicts and as it is characterised in laboratory studies in humans and 
animals.  
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Moreover, drugs of abuse may also act as a discriminative stimulus able to induce, 
maintain or enhance responding for a natural or drug reinforcer; this property may be 
evident in processes such as subjective psychoactive effects, incentive salience, 
conditioned reinforcement and drug priming.  
 
1.5.1. Drug Discrimination 
The discriminative stimulus properties of a drug are related to their subjective effects, 
and DD procedures in animals have often been used as animal models of the subjective 
effects of the compounds (Schuster and Johanson, 1988). In DD research, animal 
subjects are required to perceive the differences between the effects of drug and vehicle 
injections in order to solve a choice problem to receive food or other reinforcement. 
Although there are many variants of the procedure, the DD paradigm typically involves 
training animals to make an operant response to obtain a food pellet when treated with a 
specific drug (the so-called “training drug”), but to make an alternative response when 
treated with a placebo injection. Drugs successfully used as training drugs have ranged 
from antipsychotic to almost every class of abused drugs. Animals are trained under a 
discrete trial schedule for food pellet delivery to respond on one lever after an injection 
of nicotine training dose and on the other lever after an injection of vehicle. Two types 
of training conditions are involved. During one type of training condition experimental 
sessions are preceded by injection of nicotine; during the other type of training 
conditions sessions are preceded by injection of vehicle. The two different training 
conditions alternate daily. During nicotine-training sessions, placebo-appropriate 
responses have no consequences; during vehicle-training sessions, nicotine-appropriate 
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responses have no consequences. After a period of training-sessions like these, the 
animal becomes trained to press only the lever associated with appropriate injection 
condition. It is assumed that what drives an animal in making the correct lever choice 
are the interoceptive effects of nicotine or its vehicle, and the interoceptive effects of 
drugs in humans are thought related to their subjective effects. Training completion will 
be followed by dose-response studies for each nicotine dose in order to assess the 
relationship between dose and drug stimulus properties. Once nicotine discrimination 
training has been completed, the so-called generalization or substitution tests can be 
initiated and other drugs can be tested to determine if the occasion drug- or vehicle-
lever selection occurs. Such tests are designed to determine whether other drugs will 
generalize to, or substitute for, nicotine (they can induce nicotine- or vehicle-lever 
response). It should be noted that although cross-generalisation between two drugs 
implies that they have similar discriminative properties, it does not prove they have 
identical stimulus properties. Rats are tested for cross-generalization between nicotine at 
the training dose and four doses of test drug (including vehicle, i.e. 0 mg/kg), and each 
subject receives all doses in a Latin square design, with washout days in between.  
1.5.2. Self-administration 
Drug S/A has been widely characterized for all the drugs abused by humans, under 
different modes of administration. The paradigm has a high analogy to the pathological 
condition; it allows studying of the underlying neurobiological mechanisms, as well as 
having a high predictive validity for the identification of novel anti-addiction therapies. 
The experiments performed in this research project aim to investigate the effects of 
AChE-Is pre-treatment on nicotine S/A behaviour in rat by using a fixed-ratio schedule. 
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This conditioning protocol allows training animals to self-administer nicotine 
intravenously (i.v.) as a consequence of responding for a fixed number of presses on an 
active lever, – on a fixed-ratio (FR) of 2– in order to get an i.v. infusion from the 
infusion pump placed outside the Skinner box. Initially, animals are trained to lever 
press for a food reinforcer. They then have an i.v. cannula surgically implanted. After a 
period of recovery from surgery, rats start a training period that consists of a daily i.v. 
nicotine S/A session (lasting 1 hour) for a period of about two weeks in order to meet 
criteria of stable responding performance. Once the animals at FR1 schedule achieve 25 
infusions per session, they will advance to the following stages of training (FR2). The 
stable performance required to advance to the next stage is defined as similar number of 
infusions or similar number of active lever presses per session +/- 20% on at least three 
consecutive days. Performance is measured as number of active lever presses/hour or as 
number of infusions/hour. The number of inactive lever presses is also monitored, as a 
measure of non-specific responding and of possible adverse drug effects on rat’s motor 
activity. When the criteria of stability are reached (nicotine training), rats are pre-treated 
with AChE-Is or vehicle. Each subject receives all doses in a Latin square design, with 
washout days in between.  
1.5.3. Extinction and Relapse 
The reinstatement model is currently used in many laboratories to investigate 
mechanisms underlying relapse to drug seeking. Extinction procedure can provide 
measures of the incentive-motivational properties of drugs by assessing the persistence 
of drug-seeking behaviour in the absence of response contingent drug availability. In the 
extinction paradigm, animals are first trained to nicotine S/A until stable S/A patterns 
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are exhibited for several consecutive days. This procedure ensures that, before 
extinction testing, the animals have developed a strong drug S/A habit and thus exhibit 
resistance to extinction compared to undertrained subjects. Extinction testing sessions 
are identical to training sessions except that no drug is delivered after completion of the 
response requirements. Extinction training continues until rats reach a predetermined 
extinction criterion (e.g. 20% or less responding during the last extinction session as 
compared with the first extinction session). In subsequent test sessions, reinstatement of 
lever-pressing behaviour is defined as significantly higher responding on the lever 
previously paired with nicotine infusions (typically referred to as the active lever) 
following exposure to the experimental manipulations (drug cues or drug-priming) as 
compared with the control manipulations. 
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 2. Materials and Methods 
 
All animal procedures were carried out in accordance with the Principles of laboratory 
animal care (NIH publication No.85/23, revised 1985), the European Communities 
Council Directive of 24 November 1986 (86/609/EEC). The inter-departmental Centre 
has approved these procedures for Laboratory Animal Service and Research of the 
Verona University, according to art.7 D.L. 116/92 of the Italian Legislation. All efforts 
were made to minimise animal suffering and to keep the number of animals used as low 
as possible. 
 
2.1. Drug Discrimination 
2.1.1. Subjects 
Experimentally naïve Sprague Dawley male rats (n=11, 175-200 g, Charles River, Italy) 
were individually-housed in a temperature- and humidity-controlled colony room under 
a 12 h light/dark cycle (lights on at 6 am) and were food deprived to maintain 85% of 
their free-feeding weight with water ad libitum.  
2.1.2. Apparatus 
Experimental sessions were performed in eight identical operant conditioning chambers 
(Med Associated Inc., St Albans, VT). The front panel contained two response levers, a 
stimulus light over each response lever, and an aperture between the levers for delivery 
of sugar pellets (Bilaney Consultants Ltd., UK). A house light was located on the back 
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panel near the chamber ceiling to provide ambient illumination. Each chamber was 
enclosed in a sound-isolating box equipped with an exhaust fan that provided masking 
noise. 
2.1.3. Discrimination training  
The procedure was similar to those described by Solinas (2006). Rats were initially 
trained to lever press for food pellets during daily 20-min sessions. During this phase, 
the active lever was randomly changed every day, with response on active lever 
producing a single sugar pellet delivery. Once responding was stable (15 
reinforcers/session for at least two consecutive sessions), the fixed ratio (FR) 
requirement to obtain food was gradually increased from FR1 to FR10. When FR10 
schedule was established and stable performance was maintained (50 reinforcers/session 
for at least two consecutive sessions), the discrimination training began. Rats were 
trained to respond on one lever (right lever for half of the rats, left lever for the other 
rats) following an intraperitoneal (i.p.) injection of 0.2 mg/kg nicotine (Nic; training 
dose) and on the other lever following vehicle (0.9% saline; Sal). In this phase, one 
lever was active when training drug was injected and the other lever when vehicle was 
injected. Pressing on the correct active lever resulted in the food delivery. Rats were 
injected in the home cage and, after 10 minutes were placed in the operant chamber for 
the session start. Nicotine and vehicle daily treatments were semi-randomly alternated 
(Nic-Sal-Nic-Sal-Sal-Nic-Sal-Nic-Nic-Sal-Sal-Nic-Sal-Nic-Nic-Sal). Criteria of 
discrimination performance were achieved when responding during the first trial was 
>80% and less than 5 lever presses respectively on injection-appropriate and incorrect 
lever, for 8 consecutive sessions. Sessions were performed 5 days a week.  
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2.1.4. Nicotine dose-response curve 
Once the criteria of discrimination performance were achieved, different doses of 
nicotine were tested in order to assess a dose-response relationship. On Tuesdays and 
Fridays, different doses of nicotine (0.025, 0.05 or 0.1 mg/kg) were administered in 
order to assess the generalization level for the nicotine training dose. Intervening 
sessions consist of baseline session with nicotine training dose or vehicle to maintain 
discrimination performance. 
2.1.5. Generalization test 
Generalization test sessions occurred twice a week similarly to the nicotine dose-
response curve sessions. Tacrine (0.625, 1.25 or 2.5 mg/kg; 60 minutes prior session), 
physostigmine (0.05, 0.1 or 0.2 mg/kg; 60 minutes prior session) and galantamine (1, 3 
or 5 mg/kg, 30 minutes prior session) were administered as single dose administration, 
on separate test days. Tacrine and physostigmine were injected subcutaneously (s.c.), 
whereas galantamine was injected i.p. Pre-treatment time was chosen based on literature 
data. Brain levels of galantamine transiently increase with a maximum between 15 and 
30 minutes after s.c. injection (Geerts et al., 2005). This study also suggested that the 
optimal conditions – in terms of brain concentration - for the APL effect of galantamine 
can be achieved by doses ranging from 1.5 and 5 mg/kg in the rats. The onset of action 
of physostigmine (0.125-0.25 mg/kg) and tacrine (0.625-2.5 mg/kg) ranged between 60 
and 100 minutes after administration (Liu et al., 2000). Each drug was administered at 
different doses within-subject according to a Latin-square design.  
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2.1.6. Drugs 
(-)-Nicotine hydrogen tartrate, tacrine hydrochloride, physostigmine hemisulphate and 
galantamine hydrobromide (Sigma-Aldrich, Italy) were dissolved in saline and pH 
adjusted to 7.4. Nicotine and tacrine doses were expressed as free base, while 
physostigmine and galantamine doses were expressed as salt in order to compare to 
literature data (Yamamoto et al., 1993; Shoaib et al., 1997; Le Sage et al., 2009). All 
doses were administered in a volume of 1 mL/kg.  
2.1.7. Data analysis 
All generalization data were expressed as percentage value of drug-paired lever presses 
acquired during the first trial of session (i.e. before receiving the first reinforcement) 
compared to the total number of lever presses (active and inactive). Total number of 
responses (presses/minute) was assessed as a dependent variable for overall response 
rate effect. Rate of responding was analyzed by one-way ANOVA followed by 
Dunnett’s post-hoc tests comparing total number of lever presses/minute during 
generalization test sessions vs. vehicle or nicotine training dose sessions. Full 
generalization was defined as % Nicotine Lever Response (NLR) greater than or equal 
to 80%, while partial generalisation was defined as %NLR values ranging from 20% to 
80% (Solinas et al., 2006).  
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2.2. Self-administration 
2.2.1 Subjects 
Experimentally naïve Sprague Dawley and Lister Hooded male rats (Harlan, Italy) were 
individually-housed in a temperature- and humidity-controlled colony room under a 12 
h light/dark cycle (lights on at 7 am). Animals were food restricted to maintain their 
body weight range between 240 and 260 g (daily checked): food diet (3-4 pellets, for a 
total of 15-20 g/day) was made available after each experimental session. The 
maximum amount of sugar food pellets intake during training session was 5.4 g/day for 
those subjects meeting the criteria (see below ‘training to lever press’). Animals had ad 
libitum access to water except during experimental session (3h/day). Rats were trained 
or tested once daily. 
2.2.2. Apparatus 
Behavioural testing was conducted in eight identical operant conditioning chambers 
(Coulbourn Instruments, Lehigh Valley, Whitehall, PA, USA) encased in sound-
insulated cubicles, equipped with ventilation fans (Ugo Basile, Comerio, Italy). Each 
chamber was equipped with tow levers, symmetrically centred on the frontal panel, and 
located 12.5 cm apart, 2 cm above the grid floor. The food magazine was situated in an 
opening in a panel between the two levers, 1 cm above the floor. This opening was 
closed during nicotine S/A training. A 2 W white house light was located 26 cm above 
the food magazine and activated during the entire session duration, except during the 
Time-Out (TO= 60 seconds interval after each reinforcement in which levers are 
inactive). Right lever presses corresponding to FR values, required the schedule of 
reinforcement, produced the delivery of 45-mg sugar food pellet (Bioserv, USA) or the 
32 
 
activation of the infusion pump (model A-99Z, Razel Scientific Instruments Inc., 
Stamford, CT, USA). Nicotine or saline solutions were administered via the infusion 
pump at the volume of 0.027 mL during a 1-s period. Sugar food pellet delivery was 
signalled by the 1-s illumination of a 4 W white stimulus light located in the same hole 
of the food magazine only during the training for lever press. During nicotine or and 
reinstatement sessions, reinforcer delivery (nicotine infusion) was signalled by 1-s 
illumination of one yellow and one green light emitting diode (LED) centrally placed 
above the food magazine. During food S/A reinforcer delivery (food infusion) was 
signalled by 1-s sounding of a 2.9 Hz, 60 dB Sonalert device (defined as nicotine or 
food ‘cues’). Left lever presses (‘inactive lever presses’) did not have any consequence. 
All types of lever presses, sugar food pellet and infusion deliveries was recorded. Data 
acquisition and schedule parameters were controlled by a med-PC software (Med 
Associates Inc, Georgia, USA) running on a PC-computer interfaced with the chambers 
via interface modules (Med Associates Inc.). 
2.2.3. Training to lever press 
Following a 24-h food deprivation period, all rats were trained to lever press for a food 
as reinforcement. The final training schedule of reinforcement was a FR 2, session 
duration up to 120 reinforcements were delivered or 20 min were elapsed. Once training 
to lever press for food reinforcement (it required approximately 2 weeks), rats 
underwent surgery for implant an i.v. cannula. 
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2.2.4. Surgical procedure 
Rats were anaesthetized with 0.5 mg/kg/0.5 mL medetomidine (Domitor®, Pfizer, 
Italy), 10 mg/kg tiletamine + 10 mg/kg zolazepam (Zoletil 100®, Virbac, Italy; 0.2 
mL/kg intramuscular), and then implanted with a Silicon catheter (inner diameter 0.30 
mm, outer diameter 0.63 mm, Cam Caths, Cambridgeshire, UK) in the right jugular 
vein. Immediately after surgery, animals were medicated with 5mg/kg/1 mL 
subcutaneous carprofen (Rymadyl®, Pfizer, Italy) and 25,000,000 IU benzylpenicilline 
+ 1 g/kg dihydrostreptomycin (Rubrocillina Forte®, Intervet, Italy; 1 mL/kg 
subcutaneous), 0.5 mg/kg/0.1 mL intramuscular atipamezole (Antisedan®, Pfizer, 
Italy). Each day after recovery, animals received 0.1 mL of one i.v. injection of heparin 
solution (30 IU/mL heparin sodium, Sigma, Italy) before and after the experimental 
session. 
2.2.5. Training in the nicotine self-administration procedure 
After the recovery period, rats were trained to intravenously S/A nicotine (FR 1: 
nicotine 0.03 mg/kg/infusion; TO session 60s; session duration up to 25 infusions were 
delivered or 3 h elapsed, no priming injection). Adjustment of nicotine concentration to 
changes in rat body weight was not needed because rats’ body weight was kept stable at 
250 g (± 10g). Lever pressing during the TO period was also recorded, although it did 
not have any consequences. If the animals met the criterion of 25 infusions within the 
end of daily session, the FR value was increased to FR 2 with session duration lasting 
up to 3 h. Rats were considered to reach a stable responding on nicotine S/A under a FR 
2 schedule of reinforcement when the value of reinforcements/session did not vary more 
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than 20% between three consecutive sessions. For non food-shaped rats after reaching 
stable responding at the FR 2, the FR value was increased to FR 3. 
2.2.6. Drugs 
Nicotine hydrogen tartrate (Sigma, Italy) was dissolved in heparinised bacteriostatic 
saline (0.9% NaCl + 0.9% benzylalcohol + 1 IU/mL heparin) and pH adjusted to 7.4 
with NaOH. Nicotine unit doses are expressed as mg of free base/kg of body 
weight/infusion. Physostigmine hemisulphate (Sigma, Italy) was dissolved on the test 
day in saline solution and administered s.c. 30 minutes before session start at doses of 
0.05, 0.1 or 0.2 mg/kg. Tacrine hydrochloride (Sigma, Italy) was dissolved in 
heparinised bacteriostatic saline on the test day and administered i.v. 20 minutes before 
the session start at doses of 0.032, 0.1 or 0.32 mg/kg. All doses were administered in a 
volume of 1 mL/kg. Each drug was administered at different doses within-subject 
according to a Latin-square design with at least two daily nicotine S/A sessions between 
the three testing session. 
2.2.7. Data analysis 
Data are expressed throughout the study as mean ± SEM. Comparison among groups 
was performed by analysis of variance (ANOVA) with a number of factors as indicated 
case by case in the Results section, followed by Bonferroni’s or Dunnett’s post-hoc test 
for individual comparisons between groups. Statistical analysis was performed using 
Prism 4 (Graph Pad, La Jolla, CA, USA). 
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2.3. Extinction and relapse 
2.3.1. Subjects 
Experimentally naïve Sprague Dawley and Lister Hooded (Harlan, Italy) male rats were 
individually-housed in a temperature- and humidity-controlled colony room under a 12 
h light/dark cycle (lights on at 7 am). Animals were food restricted to maintain their 
body weight range between 240 and 260 g (daily checked): food diet (3-4 pellets, for a 
total of 15-20 g/day) was made available after each experimental session. The 
maximum amount of sugar food pellets intake during training session was 5.4 g/day for 
those subjects meeting the criteria (see below ‘training to lever press’). Animals had ad 
libitum access to water except during experimental session (3h/day). Rats were trained 
or tested once daily. 
2.3.2. Apparatus 
Behavioural testing was conducted in eight identical operant conditioning chambers 
(Coulbourn Instruments, Lehigh Valley, Whitehall, PA, USA) encased in sound-
insulated cubicles, equipped with ventilation fans (Ugo Basile, Comerio, Italy). Each 
chamber was equipped with tow levers, symmetrically centred on the frontal panel, and 
located 12.5 cm apart, 2 cm above the grid floor. The food magazine was situated in an 
opening in a panel between the two levers, 1 cm above the floor. This opening was 
closed during nicotine S/A training, extinction and reinstatement sessions. A 2 W white 
house light was located 26 cm above the food magazine and activated during the entire 
session duration, except during the TO (60 seconds interval after each reinforcement in 
which levers are inactive). Right lever presses corresponding to FR values, required the 
schedule of reinforcement, produced the delivery of 45-mg sugar food pellet (Bioser, 
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USA) or the activation of the infusion pump (model A-99Z, Razel Scientific 
Instruments Inc., Stamford, CT, USA), except during the extinction and reinstatement 
sessions. Nicotine or saline solutions were administered via the infusion pump at the 
volume of 0.04638 mL during a 1-s period. Sugar food pellet delivery was signalled by 
the 1-s illumination of a 4 W white stimulus light located in the same hole of the food 
magazine only during the training for lever press. During nicotine or and reinstatement 
sessions, reinforcer delivery (nicotine infusion) was signalled by 1-s illumination of one 
yellow and one green light emitting diode (LED) centrally placed above the food 
magazine. During food S/A reinforcer delivery (food infusion) was signalled by 1-s 
sounding of a 2.9 Hz, 60 dB Sonalert device (defined as nicotine or food ‘cues’). Left 
lever presses (‘inactive lever presses’) did not have any consequence. All types of lever 
presses, sugar food pellet and infusion deliveries was recorded. Data acquisition and 
schedule parameters were controlled by a med-PC software (Med Associates Inc, 
Georgia, USA) running on a PC-computer interfaced with the chambers via interface 
modules (Med Associates Inc.). 
2.3.3. Training to lever press 
Following a 24-h food deprivation period, all rats were trained to lever press for a food 
as reinforcement. The final training schedule of reinforcement was a FR 2, session 
duration up to 60 min. Once training to lever press for food reinforcement (it required 
approximately 2 weeks), rats underwent surgery to implant an i.v. cannula. 
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2.3.4. Surgical procedure and training to nicotine self-administration 
The surgical procedure and training to nicotine S/A were the same as those described in 
the Self-administration section 2.2.4 and 2.2.5, respectively. 
2.3.5. Extinction, nicotine cues and priming reinstatement sessions 
Extinction of responding for nicotine infusion started when responding was stable (see 
training in the nicotine self-administration procedure). The extinction schedule 
consisted of a 1-h daily session where the 1-s infusion of saline - but not nicotine cues 
(1 s illumination of yellow LED, green LED and tone sounding) - was obtained by 
animals upon responding on previously nicotine-paired lever. Animals, randomized into 
two groups, were pre-treated i.v. with 0.032 mg/kg/mL tacrine or saline 1 mL/kg, 20 
minutes prior the session start. The substitution of nicotine with saline (after 10 sessions 
S/A) induced a gradual decrease of responding. Extinction criterion was defined when 
nicotine-paired lever pressing during the first hour of the session reached a value <50% 
of nicotine-paired lever value at the first extinction session. 
Rats were tested for the effect of tacrine (0.032 mg/kg/mL, i.v., 20 min pre-treatment) 
on nicotine cue-induced reinstatement of responding. During the reinstatement session, 
nicotine cues were contingently presented upon responding: FR 2 = 1 s illumination of 
yellow and one green LED centrally placed above the food magazine, and 1-s sounding 
of a 2.9 Hz, 60dB Sonalert device, infusion of saline; TO 60-s period, session duration 1 
h.  
Twenty-four hours after the cue reinstatement session, animals underwent two days of 
extinction sessions (as described above) and subsequently the rats were tested for the 
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effect of tacrine (0.032 mg/kg/mL, i.v., 20 min pre-treatment) on nicotine priming-
induced reinstatement of responding. During the priming-induced reinstatement session, 
animals were administered with a s.c. injection of nicotine 0.15 mg/kg/mL immediately 
before the session start. During the session, the nicotine-associated cues (e.g. yellow 
and green LED and sounding) were not presented upon responding on the nicotine 
active lever. 
2.3.6. Drugs 
Nicotine hydrogen tartrate (Sigma, Italy) in heparinised bacteriostatic saline (0.9% 
NaCl + 0.9% benzylalcohol + 1 IU/mL heparin) and pH adjusted to 7.4 with NaOH. 
Nicotine hydrogen tartrate for the priming-reinstatement test was administered s.c. at 
0.15 mg/kg. Nicotine unit doses are expressed as mg of free base/kg of body 
weight/infusion. 
Tacrine hydrochloride (Sigma, Italy) was dissolved in heparinised bacteriostatic saline 
on the test day and administered i.v. 20 minutes before the session start at dose 0.32 
mg/kg. All doses were administered in a volume of 1 mL/kg. Chronic treatment of 
tacrine or saline on the cue- or priming-induced reinstatement of responding has been 
tested in one group of randomized rats. 
2.3.7. Data analysis 
Data are expressed throughout the study as mean ± SEM. Comparison among groups 
was performed by analysis of variance (ANOVA) with a number of factors as indicated 
case by case in the Results section. Mann Whitney non-parametric test was applied to 
compare the number of active lever presses and inactive lever presses between different 
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treatment groups in the cue-induced reinstatement sessions. Welch non-parametric test 
was applied to compare the number of active lever presses and inactive lever presses 
between different treatment groups in the priming-induced reinstatement sessions 
Statistical analysis was performed using Prism 4 (Graph Pad, La Jolla, CA, USA). 
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 3. Results 
 
3.1. Drug Discrimination 
 
In rats trained to discriminate nicotine from vehicle, 0.025, 0.05 and 0.1 mg/kg nicotine 
produced dose-related generalization of 52.7%, 69.9% and 80.4% of total response on 
the nicotine-associated lever, respectively (Figure 3, panel A). Nicotine tested at 0.1 and 
0.2 mg/kg induced a statistically significant (p<0.05) increase in rate of responding 
compared to vehicle (78.2 ± 8.7 and 77.1 ± 8.6 vs. 57.4 ± 6 lever/presses, mean ± 
S.E.M.) (Figure 3, panel B). 
Tacrine failed to generalize for nicotine at the dose of 1.25 mg/kg, and partially 
generalized at 0.065 and 2.5 mg/kg, producing 18.3%, 29.5% or 43.6% of NLR, 
respectively (Figure 4, panel A). Tacrine did not affect rate of responding compared to 
vehicle at all doses tested. However, when comparing tacrine to nicotine there was a 
significant decrease (p<0.05) of the responding rate at 1.25 and 2.5 mg/kg tacrine 
compared to nicotine 0.2 mg/kg (59.9 ± 6.1 and 60.9 ± 8.6 vs 77.1 ± 8.6 lever 
presses/min; mean ± S.E.M.) (Figure 4, panel B).  
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Figure 3. Nicotine discrimination dose-response curve. 
Panel A. Nicotine discrimination is expressed as percentage (mean ± S.E.M.) of nicotine lever responses 
(NLR; ordinates) at nicotine doses 0.025, 0.05, 0.1, 0.2 (solid squares) or vehicle (open square) (mg/kg 
plotted in a logarithmic scale; i.p.; abscissa). Panel B. Rate of responding is expressed as number of lever 
presses/min (mean ± S.E.M.; ordinates) at the same nicotine doses as in Panel A (mg/Kg i.p.; abscissa). ## 
= P ≤ 0.01 vs. vehicle group, Dunnett’s test, n = 11 subjects. 
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Figure 4. Tacrine discrimination dose-response curve.  
Panel A. Tacrine discrimination is expressed as percentage (mean ± S.E.M.) of nicotine lever responses 
(NLR; ordinates) at tacrine doses 0.625, 1.25, 2.5 (open circle) compared to nicotine discrimination dose-
response curve (solid square) and vehicle (open square) (mg/kg plotted in a logarithmic scale; s.c.; 
abscissa). Panel B. Rate of responding is expressed as number of lever presses/min (mean ± S.E.M.; 
ordinates) at the same tacrine and nicotine doses as in Panel A (mg/Kg s.c.; abscissa). *= P ≤ 0.05 vs. 
nicotine, Dunnett’s test, n = 11 subjects. 
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Physostigmine partially generalized for nicotine at all doses tested (0.05, 0.1 or 0.2 
mg/kg), producing 40.1%, 55.1% or 43.7% of NLR, respectively (Figure 5, panel A). 
The rate of responding at the highest tested dose of physostigmine (0.2 mg/kg) was 
significantly decreased (p<0.01) compared to vehicle (39.2 ± 9.3 vs. 57.4 ± 6, lever 
presses/min; mean ± S.E.M.) and all doses induced a significant decrease (p<0.05 0.05 
mg/Kg; p<0.01 0.1 and 0.2 mg/kg) compared to nicotine training dose (57.0 ± 6.3, 49.7 
± 6.2 and 39.2 ± 9.3 vs 77.1 ± 8.6 lever presses/min; mean ± S.E.M.) (Figure 5, panel 
B). 
Galantamine partially generalized for nicotine at all doses tested (1, 3 or 5 mg/Kg), 
producing 34.6%, 60.6% or 62.2% of NLR, respectively (Figure 6, panel A). 
Galantamine (5 mg/kg) induced a lower rate of responding (p<0.01) compared to 
vehicle (34.2 ± 6.9 vs. 57.4 ± 6 lever presses/min; mean ± S.E.M.) and all doses tested 
induced a statistically significant decrease in rate of responding (p<0.05 1 mg/kg; 
p<0.01 3 and 5 mg/kg) compared to nicotine training dose (60.9 ± 7.9, 53.4 ± 8.4 and 
34.2 ± 6.9 vs 77.1 ± 8.6 lever presses/min; mean  ± S.E.M.) (Figure 6, panel B).  
Animals were also observed in the home cage after administration of all drugs for the 
assessment of gross behavioural changes. Following administration of 5 mg/kg 
galantamine, 0.2 mg/kg physostigmine and 2.5 mg/kg tacrine, slight yawing and limb 
tremors were observed in few animals. All other doses were without overt behavioural 
effects. 
 
44 
 
  
Figure 5. Physostigmine discrimination dose-response curve.  
Panel A. Physostigmine discrimination is expressed as percentage (mean ± S.E.M.) of nicotine lever 
responses (NLR; ordinates) at physostigmine doses 0.05, 0.1, 0.2 (open circle) compared to nicotine 
discrimination dose-response curve (solid square) and vehicle (open square) (mg/kg plotted in a 
logarithmic scale; s.c.; abscissa). Panel B. Rate of responding is expressed as number of lever presses/min 
(mean ± S.E.M.; ordinates) at the same physostigmine and nicotine doses as in Panel A (mg/kg s.c.; 
abscissa). ## = P ≤ 0.01 vs. vehicle; *= P ≤ 0.05 and ** = P ≤ 0.01 vs. nicotine 0.2 mg/Kg dose; Dunnett’s 
test, n = 11 subjects. 
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Figure 6. Galantamine discrimination dose-response curve.  
Panel A. Physostigmine discrimination is expressed as percentage (mean ± S.E.M.) of nicotine lever 
responses (NLR; ordinates) at galantamine doses 1, 3, 5 (open circle) compared to nicotine discrimination 
dose-response curve (solid square) and vehicle (open square) (mg/kg plotted in a logarithmic scale; s.c.; 
abscissa). Panel B. Rate of responding is expressed as number of lever presses/min (mean ± S.E.M.; 
ordinates) at the same galantamine and nicotine doses as in Panel A (mg/Kg s.c.; abscissa).  ## = P ≤ 0.01 
vs. vehicle; * = P ≤ 0.05 ** = P ≤ 0.01 vs. nicotine 0.2 mg/kg dose; Dunnett’s test, n = 11 subjects 
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3.2. Self-administration 
3.2.1. Effect of physostigmine on nicotine self-administration 
Physostigmine at 0.05, 0.1 or 0.2 mg/kg has been tested in rats trained to self-
administered nicotine. ANOVA analysis for 1-factor [Pre-treatment – 4 levels] shows 
that physostigmine pre-treatment did not induced any significant changes on the number 
of nicotine infusion during 60 minutes session (ANOVA, F [3,24]=2.183; P=0.067; 
n=9). However a trend of increase and decrease in the number of nicotine infusion is 
noted after the administration of physostigmine at 0.05 and 0.2 mg/kg, respectively.  
The mean nicotine infusion/1h values measured during test sessions were 9.3±2.7 with 
saline, 12.3±2.8 with physostigmine 0.05 mg/kg, 8.1±3.5 with physostigmine 0.1 mg/kg 
and 2.9±1.2 with physostigmine 0.2 mg/kg (Figure 7)  
 
 
Figure 7. Effects of physostigmine pre-treatment on number of responding for nicotine infusion/session.  
Physostigmine (0.05, 0.1 or 0.2 mg/kg s.c.) or vehicle (0 mg/kg) was given 30 minutes before the self-
administration session start. Data represent the number of nicotine infision /session (mean±SEM; n=9).  
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The number of active lever presses during test session was 35.9±10.6 for saline, 
53.2±11.7 for physostigmine 0.05 mg/kg, 30.0±12.9 with physostigmine 0.1 mg/kg, 
11.3±4.5 with physostigmine 0.2 mg/kg. The number of lever presses on the inactive 
lever during test session was 2.2±0.8 for saline, 12.1±4.7 for physostigmine 0.05 mg/kg, 
1.2±1.0 for physostigmine 0.1 mg/kg and 0.6±0.2 for physostigmine 0.2 mg/kg. (Figure 
8). The increase of the number of inactive lever presses after 0.05 mg/kg physostigmine 
administration is associated with an increased locomotor activity 
 
 
Figure 8. Effect of physostigmine on active and inactive lever presses. 
Physostigmine (0.05, 0.1 or 0.2 mg/kg s.c.) or vehicle (0 mg/kg)  was given 30 minutes before the self-
administration session start. Solid bars represent the number of presses on active lever (nicotine-paired 
lever), open bars represent the number of presses on inactive lever (mean±SEM; n=9). 
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Test sessions have been performed when each animal reached the stability criterion, 
which required different number of training session between test sessions. To evaluate 
the effect of physostigmine pre-treatment the difference in the number of infusions 
during pre-test days needs to be taken into account (Figure 9).  
 
 
Figure 9. Effect of physostigmine on the number of infusion during pre-test and test days. 
Physostigmine (0.05, 0.1 or 0.2 mg/kg s.c.) or vehicle (0 mg/kg) was given 30 minutes before the self-
administration session start. White open bars represent the number of nicotine infusions on the pre-test 
sessions, black solid bars represent the number of nicotine infusions on the test days (mean±SEM; n=9). 
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Being this difference not statistically significant, the mean values of the difference 
between the number of infusions during pre-test and test days for each physostigmine 
doses was considered (delta; Figure 10). 
The graph of difference depending on physostigmine dose regimen assumed a bell-
shape profile with a trend of non statistically significant increase and decrease in the 
mean number of nicotine infusions after physostigmine administration of  0.05 mg/kg 
and 0.2 mg/kg, respectively (ANOVA, F[3,24]=0.569;P=NS; n=9). 
 
Figure 10. Effect of physostigmine on the nicotine reinforcements difference between pre-test and test 
session.  
Physostigmine (0.05, 0.1 or 0.2 mg/kg s.c.) or vehicle (0 mg/kg) was given 30 minutes before the self-
administration session start. Solid black columns represent thrmaen values of difference between number 
of nicotine infusion received during pre-test and test sessions (mean±SEM; n=9). 
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When the cumulative curve of nicotine number of infusions was analysed for the entire 
session, an effect compared to pre-test at 10 and 20 minutes was observed. 
Consequentially, the time-course of the mean number of infusion at different time point 
was analysed (Figure 11). ANOVA analysis for 2-factor [Pre-treatment – 4 levels X 
time 3 levels] shows a non significant interaction (F[6,32]=1.587; NS) but a statistically 
significant effect of pre-treatment (F[3.32]=3.106; P=0.040). Considering the delta 
values time-course, the ANOVA analysis for 2-factor [Pre-treatment – 4 levels X time 3 
levels] does not show statistical significance compared to pre-treatment factor 
(F[3,32]=0.802; P=0.50), but a trend of decrease in the number of infusion with 
physostigmine 0.2 mg/kg and a trend of increase with physostigmine 0.05 mg/kg is 
observed (Figure 12).  
 
Figure 11. Time couse of physostigmine pre-treatment effects on number of nicotine infusions.  
Physostigmine was given 30 minutes before the self-administration session start. Data in ordinates 
represent the number of cumulative nicotine infusions (mean±SEM; n=9) at different time bins during 
nicotine self-administration session after pre-treatment with vehicle (blue square) or physostigmine at 
0.05 mg/kg (green triangle), 0.1 mgk/kg (orange triangle) and 0.2 mg/kg (red diamond). Data in abscissa 
represent the session time duration expressed in minutes. (* = P ≤ 0.05 ANOVA vs main effect Pre-
treatment factor). 
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Figure 12. Time couse of physostigmine pre-treatment effects on reinforcement difference between pre-
test and test sessions.  
Physostigmine was given 30 minutes before the self-administration session start. Data in ordinates 
represent the difference in number of nicotine infusion between pre-test and test session (mean±SEM; 
n=9) at different time bins during nicotine self-administration session after pre-treatment with vehicle 
(blue square) or  physostigmine at 0.05 mg/kg (green triangle),  0.1 mgk/kg (orange triangle) and 0.2 
mg/kg (red diamond). Data in  represent the session time duration expressed in minutes.  
 
 
Animal administered with physostigmine 0.2 mg/kg, showed some side effect as limbs 
tremors and mandibular vertical movements.   
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3.2.2. Effect of tacrine on nicotine self-administration 
Tacrine at 0.032, 0.1 or 0.32 mg/kg has been tested in rats trained to self-administered 
nicotine. ANOVA analysis for 1-factor [Pre-treatment – 4 levels] shows that tacrine pre-
treatment did not induced any significant changes on the number of nicotine infusion 
during 60 minutes session (ANOVA, F [3,16]=0.633; P=0.605; n=5). However a trend 
of increase in the number of nicotine infusion is noted after the administration of tacrine 
at 0.1mg/kg.  
The mean nicotine-paired lever/1h values measured during test sessions were 11.0±1.6 
with saline, 10.6±1.7 with tacrine 0.032 mg/kg, 14.2±2.1 with tacrine 0.1 mg/kg and 
12.4±2.6 with tacrine 0.32 mg/kg (Figure 13) 
 
Figure 13. Effects of tacrine pre-treatment on number of nicotine infusion/session.  
Tacrine (0.032, 0.1 or 0.32 mg/kg i.v.) or vehicle (0 mg/kg) was given 20 minutes before the self-
administration session start. Data represent the number of nicotine infusions/session (mean±SEM; n=5).  
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The number of active lever presses during test session was 45.2±9.8 for saline, 
46.0±11.6 for tacrine 0.032 mg/kg, 81.4±17.7 with tacrine 0.1 mg/kg, 49.8±13.3 with 
tacrine 0.32 mg/kg. (Figure 14).The number of lever presses on inactive lever during 
test session was 4.4±1.6 for saline, 6.8±3.3 for tacrine 0.032 mg/kg, 4.4±1.8 for tacrine 
0.1 mg/kg and 3.2±1.7 for tacrine 0.32 mg/kg. 
 
Figure 14. Effect of tacrine on active and incative lever presses. 
Tacrine (0.032, 0.1 or 0.32 mg/kg i.v.) or vehicle (0 mg/kg) was given 20 minutes before the self-
administration session start. Solid bars represent the number of presses on active lever (nicotine-paired 
lever), open bars represent the number of presses on inactive lever (mean±SEM; n=5). 
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Figure 15 shows the mean values of the number of infusions during pre-test compared 
to test for each tacrine doses.  
 
 
Figure 15. Effect tacrine on the number of infusion during pre-test and test days. 
Tacrine (0.032, 0.1 or 0.32 mg/kg i.v.) or vehicle (0 mg/kg) was given 30 minutes before the self-
administration session start. White open bars represent the number of nicotine infusions on the pre-test 
sessions, black solid bars represent the number of nicotine infusions on the test days (mean±SEM; n=5). 
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The mean values of the difference between the number of infusions during pre-test and 
test days for each tacrine doses (delta; Figure 16) does not show any significant 
difference (ANOVA, F[3,16]=0.447; P=0.723; n=5). 
 
 
Figure 16. Effect of tacrine on the nicotine reinforcements difference between pre-test and test session.  
Tacrine (0.032, 0.1 or 0.32 mg/kg i.v.) or vehicle (0 mg/kg) was given 20 minutes before the self-
administration session start. Solid black columns represent the mean values of difference between number 
of nicotine infusion received during pre-test and test sessions (mean±SEM; n=5). 
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When cumulative curves of the number of nicotine infusions were analysed for the 
entire session, an effect compared to pre-test at 5, 10 or 30 minutes was observed. 
Consequentially, the time-curse of the mean number of infusion at different time point 
was analysed (Figure 17). 
 
 
Figure 17. Time couse of tacrine pre-treatment effects on number of nicotine infusions.  
Tacrine was given i.v. 20 minutes before the self-administration session start. Data in ordinates represent 
the number of cumulative nicotine infusions (mean±SEM; n=5) at different time bins during nicotine self-
administration session after pre-treatment with vehicle (blue square) or  tacrine at 0.032 mg/kg (green 
triangle), 0.1 mgk/kg (orange trianglee) and 0.32 mg/kg (red diamond). Data in abscissa represent the 
session time duration expressed in minutes.  
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ANOVA analysis for 2-factor [Pre-treatment – 4 levels X time 4 levels] shows neither a 
non significant interaction (F[9,13]=0.519; P=0.852) nor a  significant effect of pre-
treatment (F[3,13]=0.495; P=0.692). ANOVA analysis for 1-factor [Pre-treatment – 4 
levels] at 5, 10 and 30 minutes also does not show any significant effect: ANOVA 
F[3,16]=0.195; P=0.898, ANOVA F[3,16]=0.546; P=0.659 and ANOVA 
F[3,16]=0.529; P=0.669, respectively. Considering the delta values time-course, the 
ANOVA analysis for 2-factor [Pre-treatment – 4 levels X time 4 levels] does not show 
statistical significance compared to pre-treatment factor (F[3,16]=0.720; P=0.555), but a 
trend of increase in the number of infusion after tacrine 0.032 administration at 5, 10 
and 30 minutes mg/kg is observed (Figure 18).  
 
Figure 18. Time couse of tacrine pre-treatment effects on reinforcement difference between pre-test and 
test sessions.  
Tacrine was given i.v. 20 minutes before the self-administration session start. Data in ordinates represent 
the difference in number of nicotine infusion between pre-test and test session (mean±SEM; n=5) at 
different time bins during nicotine self-administration session after pre-treatment with vehicle (blue 
square) or  tacrine at 0.032 mg/kg (green triangle), 0.1 mgk/kg (orange triangle) and 0.32 mg/kg (red 
diamond). Data in  abscissa represent the session time duration expressed in minutes.  
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 3.3. Extinction and relapse 
3.3.1. Effect of chronic tacrine treatment on extinction of responding for nicotine 
self-administration 
Chronic tacrine treatment has been tested in two separated rat groups that underwent 10 
sessions of extinction of responding for nicotine self-administration. As showed in 
Figure 19 the mean number of active lever pressing is reduced between the first and the 
last day of extinction in both treatment groups. The mean number of active lever 
pressing in saline group was 18.9±3.61 at first day, 8±1.65; 15.45±3.63; 12.18±2.64; 
11.36V3.41; 7.63±1.14; 10.18±2.65; 9.27±1.66; 10.81±1.61; 8.27±0.98 at the next days  
from the second to the tenth, respectively. 
 
Figure 19. Tacrine effect on extinction of nicotine self-administration behaviour.  
Data in ordinates represent the number of cumulative active nicotine-related lever presses (mean±SEM; 
n=11) during the last nicotine self-administration session for vehicle group (blue square) or tacrine group 
(0.32 mg/kg i.v.; red square) and the last three extinction  sessions for vehicle group (white square) or 
tacrine group (0.32 mg/kg i.v.; black square).  
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The comparison of the mean number of active lever pressing between saline and tacrine 
treatment group during the 10 extinction sessions does not show any statistically 
significant difference for treatment factor (ANOVA analysis for 2-factor; F [1;20]= 1; 
P=0.436) (Figure 20). 
 
 
Figure 20. Tacrine effect on active or inactive lever presses during extinction.  
Data in ordinates represent the number of lever presses (mean±SEM; n=11) on active nicotine-related 
lever (saline group blue circle; tacrine group 0.32 mg/kg i.v. red circle) or inactive lever (saline group 
blue square; tacrine group0.32 mg/kg i.v. red square) during ten consecutive 1 hour-extinction session. 
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3.3.2. Effect of tacrine on nicotine cue-induced reinstatement of responding 
The rats were tested for prevention of nicotine-cue induced reinstatement of responding 
after tacrine or saline treatment.  Pre-treatment with tacrine 0.32 mg/kg did not induce 
any significant changes of nicotine cue-induced reinstatement of responding (Figure 
21). The mean nicotine-paired lever/1-h values measured during reinstatement session 
were, respectively, 19.54±3.52 after saline and 27.09±6.62 after tacrine 0.32 mg/kg 
(Mann Whitney test, P=0.346).  The number of inactive lever presses during 
reinstatement session was 3.27±1.28 after saline and 1.27±0.46 after tacrine group 
(Mann Whitney test, P=0.157). 
 
Figure 21. Tacrine effect on nicotine cue-induced reinstatement of responding. 
Data in ordinates represent the number of lever presses (mean±SEM; n=11) on active nicotine-related 
lever (saline group solid blue bar; tacrine group 0.32 mg/kg i.v. solid red bar) or inactive lever (saline 
group open blue bar; tacrine group 0.32 mg/kg i.v. open  red bar) during 1 hour-cue-induced 
reinstatement session. 
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 3.3.3. Effect of tacrine on nicotine priming-induced reinstatement of responding 
The rats were tested for prevention of priming induced reinstatement of responding after 
tacrine or saline treatment. Pre-treatment with tacrine 0.32 mg/kg did not induce any 
significant changes of nicotine priming-induced reinstatement of responding (Figure 
22). The mean nicotine-paired lever/1-h values measured during reinstatement session 
were, respectively, 19.7±4.4 after saline and 25±7.91 after tacrine 0.32 mg/kg (Welch t 
test, P=0.283). The number of inactive lever presses during reinstatement session was 
0.7±0.49 after saline and 2.18±0.65 after tacrine group (Mann Whitney test, P=0.086). 
 
 
Figure 22. Tacrine effect on nicotine priming-induced reinstatement of responding. 
Data in ordinates represent the number of lever presses (mean±SEM; n=11) on active nicotine-related 
lever (saline group solid blue bar; tacrine group 0.32 mg/kg i.v. solid red bar) or inactive lever (saline 
group open blue bar; tacrine group 0.32 mg/kg i.v. open  red bar) during 1 hour-priming-induced 
reinstatement session. 
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 4. Discussion 
 
In this research project three AChE-Is have been tested in three different animal models 
of nicotine dependence. The results can be summarised as follows: i) the two AChE-Is 
with APL properties, physostigmine and galantamine, induced partial generalization for 
nicotine discriminative stimulus; tacrine, a non-APL AChE-I, did not generalize for 
nicotine to nicotine, except at the highest tested dose; ii) physostigmine and tacrine 
administered pre-treatment did not exert any effect on nicotine S/A; iii) chronic tacrine 
treatment did not induced any significant changes on extinction of responding for 
nicotine S/A model and on nicotine cue and priming-induced reinstatement of 
responding paradigm. 
Drug Discrimination 
The first study of this research was designed to investigate whether AChE-Is with APL 
properties at nAChRs generalize to nicotine interoceptive stimulus and the operant 
behavioural model applied is the DD. DD methodology provides an approach for 
objective, quantitative study of the perception of psychoactive drug effects that can be 
applied to substances across numerous pharmacological classes in either human or 
animal subjects (Smith and Stolerman, 2009). The strengths of this model are the 
molecular specificity of the discriminative-stimulus effect of a drug, the correspondence 
between neurochemical and molecular mechanisms of action and behavioural measures, 
and the high predictive validity for subjective effects in man (Solinas, 2006). Nicotine 
produces an interoceptive stimulus that has been extensively studied pharmacologically 
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in the rat.  Agonists acting at nAChRs, but not mAChRs, generalize to the nicotine cue 
(Pratt et al., 1983; Wiley 1996; Chandler and Stolerman 1997; Smith and Stolerman 
2009). This DD paradigm was thus used in the current study as in vivo model for testing 
the effect the nicotine-like effects of AChE-Is on nAChRs. 
In the current study, the two AChE-Is with APL properties on nAChRs, physostigmine 
and galantamine, induced partial generalization for nicotine discriminative stimulus; the 
highest degree of generalization was induced by 5 mg/kg galantamine. The degree of 
generalization observed with physostigmine and galantamine was greater than that 
induced by tacrine. Tacrine, a non-APL AChE-I, did not generalize for nicotine except 
for the highest dose tested which showed a partial generalisation. Galantamine dose-
dependently induced nicotine-appropriate lever responding, but this effect was 
associated with a decrease in rate of responding.  Physostigmine partially generalized 
for nicotine discriminative stimulus, with no clear dose-response relationship, however 
the decrease in the rate of responding was directly proportional to the dose. Therefore, it 
is possible that the reduced rate of responding could mask higher nicotine-appropriate 
lever presses, thus the degree of generalization observed was underestimated. 
Neurobehavioural side-effects (e.g., tremors, decreased locomotor activity) associated 
with galantamine and physostigmine administration has been reported in the literature 
(Sweeney et al., 1990; Mach et al., 2004; Myher et al., 2010). The behavioural signs 
observed at higher doses of both physostigmine and tacrine were oral movements 
(tongue protrusion and repeated chewing) and in some cases fasciculation. Tacrine (5 
mg/kg) produced motor side effects which disrupt operant performance in the study 
performed by Liu et al. (2000).  It is interesting to note that tacrine was reported to have 
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an opposite effect on ACh release at higher doses (Svensson et al., 1996). Furthermore, 
in vivo studies showed an inverted U-shaped response curves with rivastigmine as well 
as with other AChE-Is such as tacrine and galantamine (Yoshida and Suzuki 1993; 
Sweeney et al., 1990). Is it possible that this AChE-Is pharmacodynamic feature in vivo 
may explain the lack of dose-response generalization.  
Both Chandler and Stolerman (1997) and Rollema et al. (2007) have demonstrated that 
the nAChRs partial agonist cytisine exhibited a full dose-related generalization to 
nicotine. Other studies have shown that the partial agonists cytisine and varenicline only 
partially generalize to nicotine (Smith et al., 2007). In particular, LeSage et al., (2009) 
demonstrated that varenicline and cytisine generalized to the nicotine stimulus to 
different extents, with varenicline showing greater generalization that cytisine.  
This study demonstrated that AChE-Is induced partially nicotine-like effect, but the 
main limitation was the lack of assessment whether the dose-relationship of the 
generalization effect of AChE-Is vs. nicotine stimulus was dependent upon ACh levels. 
Systemic AChE-Is -increased ACh levels may activate mAChRs and nAChRs, both at 
pre-synaptic and post-synaptic level, thereby enhancing and prolonging the action of 
ACh on both classes of AChRs. One hypothesis is that treatment with AChE-Is could 
alter the spatio-temporal pattern of ACh levels maintained by AChE. Inhibition of 
AChE would allow for a wider spatial diffusion of ACh over a longer period of time, 
with the prediction that it would result in a larger and prolonged endogenous agonist 
binding at synaptic and non-synaptic AChRs. This effect could have a greater impact on 
the activation of nAChRs than mAChRs. In fact, ACh-induced activation of nAChRs 
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for a prolonged period of time would increase the probability of nAChRs transition to a 
desensitized state. 
 
Self-administration 
Following the DD experiments that allowed a pharmacological characterisation of 
AChE-Is, physostigmine and tacrine have been selected as tool compound for the 
nicotine S/A study. Intravenous S/A model is generally considered to be the most direct 
measure of drug’s reinforcing effect (Le Foll and Goldberg, 2009). Although some of 
the early attempts to establish nicotine as a reinforcer met with limited success, it has 
now been demonstrated that animals do work to obtain nicotine. When delivered 
intravenously, nicotine maintains S/A behaviour in a variety of animal species, 
including primates (Goldberg et al., 1981; Sannerud et al., 1994) and rodents (Corrigall 
and Coen, 1989; Donny et al., 1995; Tessari et al., 1995; Shoaib et al., 1997). A review 
of methodological details of nicotine S/A can be found in Corrigall (1999).  
Physostigmine has been selected as representative of the AChE-Is with APL properties, 
and tacrine as representative of AChE-Is with no APL properties. In this study rats have 
been trained to self-administered nicotine and after a training period they received pre-
treatment with physostigmine or tacrine. Physostigmine pre-treatment at 0.05, 0.1 and 
0.2 mg/kg did not induce any significant changes on the number of nicotine infusion 
during 60 minutes session. However a trend of increase and decrease in the number of 
nicotine infusion is noted after the administration of physostigmine at 0.05 and 0.2 
mg/kg, respectively. The effect of increase in number of nicotine injection after 
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administration of physostigmine at 0.05 mg/kg is associated with an increase in number 
of lever presses and with an increase in locomotor activity. It cannot be excluded that 
this effect could be due to increase changes of pressing the lever as consequence of 
increased activity of the animals in the box. The decreasing in number of nicotine 
injections that appeared with physostigmine 0.2 mg/kg is associated with a decreased 
number of lever pressing. It is important to note that the rate reducing effect of high 
systemic dose (0.2 mg/kg) of physostigmine may result in part from nonspecific effects 
of systemic cholinergic activation, as described by Wilson and Schuster (1973) in 
primates and as reported by Zhou et al. (2007). 
Within the same nicotine S/A experiment, tacrine at 0.032, 0.1 or 0.32 mg/kg has been 
administered as a pre-treatment. Results showed that tacrine pre-treatment did not 
induce any significant changes on the number of nicotine infusion during a 60 minutes 
session. However a trend of increase in the number of nicotine infusion is noted after 
administration of tacrine at 0.1mg/kg.  
 In the VTA, carbachol and cytosine, a nicotine agonist, induced conditioned place 
preference (CPP) which is a commonly used paradigm to assess the strength of stimulus 
associated with drugs (Yeomans et al., 1985; Museo & Wise, 1994). Furthermore, 
lesions of the pedunculo-pontine nucleus inhibit morphine and amphetamine CPP 
(Bechara and van der Kooy, 1989; Olmstead & Franklin, 1993). These results indicate 
that VTA stimulation of both mAChRs and nAChRs are critical for the expression of 
conditioned reinforcement. In contrast, administration of AChE-Is into the NA 
suppressed cocaine- and morphine-induced CPP (Hikida et al., 2003) and also 
reinstatement of heroin seeking (Zhou et al., 2007). Consistently with these results, a 
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lower dose of cocaine was needed for example to induce CPP in mice in which NA was 
ablated with an immunotoxin (Hikida et al., 2001). It is important to note that the effect 
of AChE-Is in NA are similar to those obtained when they are systemically 
administered.  
Systemic administration of physostigmine reduced cocaine S/A in rhesus monkeys (De 
La Garza & Johanson, 1982). Kameda et al. (2000) showed that drinking tacrine for six 
days enhanced nicotine preference and intake in the following six days in a 2-bottle 
choice paradigm. Since similar enhancing effects were observed after treatment with 
oral mecamylamine under the same conditions, the authors concluded that the increased 
nicotine consumption was due to a compensatory intake for the reduced reward induced 
by blocking (with mecamylamine) or by indirectly activating (with tacrine) nAChRs. 
Grasing et al. (2008) reported that tacrine induced a dose-related inhibition of cocaine 
and food S/A in rats, and confirmed previous results from Liu et al. (2000) on water 
S/A. Systemic donepezil reduced morphine and cocaine CPP and hyperlocomotion in 
mice (Hikida et al., 2003), and these effects were reversed by selective immunotoxin 
cholinergic lesion in the NA (Kaneko et al., 2000; Hikida et al., 2001). Interesting data 
were collected when the effects of donepezil on methamphetamine-seeking behaviour 
were investigated both systemically and intracranially (Hiranita et al., 2006). Overall, 
these data strongly indicated that the effects of AChE-Is resulted from an increase of 
nAChR-ergic transmission and they were consistent with the hypothesis that chronic 
methamphetamine decreases choline acetyltransferase (ChAT) and increases vescicular 
ACh transporter (VAChT) in humans (Kish et al., 1999; Siegal et al., 2004). In fact, 
Siegal et al. showed that chronic administration of large doses of methamphetamine, but 
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not cocaine and heroin, decreased brain ChAT activity, which was presumably 
compensated by over-expressed VAChT. Kish et al. (1999) found a severe decrease of 
ChAT (up to 94%) only in post-mortem brains of methamphetamine users who had the 
highest drug levels, whereas no significant changes were observed in post-mortem 
brains of cocaine dependent individuals. Hiranita et al. (2006) speculated that this 
cholinergic imbalance may result from down-regulated nAChR-ergic transmission in 
the striatum. This would explain why donepezil and nicotine, by enhancing nAChR-
ergic transmission, were effective against methamphetamine reinstatement. 
Unfortunatly, the study lacks information about the effects of donepezil in the VTA, 
which would have been interesting considering the differential outcomes generated 
when AChE-Is are microinjected into the VTA compared to the NA. Also, the data in 
methamphetamine users (Kish et al., 1999; Siegal et al., 2004) indicated a general 
cholinergic down-regulation and therefore did not exclude an involvement of mAChRs. 
Opposite results were obtained however by Takamatsu et al. (2006), that showed 
divergent findings on the effects of systemic administration of donepezil (at doses 
approximately ten-fold greater than those used by Hiranita et al., 2006) on cocaine but 
not methamphetamine reward in mice. For example, donepezil reduced cocaine-induced 
CPP, hyperlocomotion and motor sensitization, but this inhibition was not observed in 
methamphetamine treated mice. More recent studies did not improve the unclear 
scenario. In fact, discrepancies are still present on the effects of AChE inhibition, 
depending on the AChE-I used, the route of administration, and the type of drug of 
abuse investigated.  The most conservative hypothetical framework is to consider a 
different role of cholinergic modulation of DA transmission at the VTA cell bodies and 
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at the NA terminals levels, with a more relevant role of nAChRs at the former and of 
mAChRs at the latter. According to this hypothesis, Zhou et al (2007) showed that 
systemic administration of physostigmine reduced heroin S/A and seeking behaviour in 
rats. This effect was likely the result of mAChRs stimulation since it was reversed by 
pre-treatment with scopolamine.  
The schematic hypothetical framework based on the scientific evidence, suggest that: i), 
increase in ACh levels in the VTA increases dopaminergic neuronal activity and, on the 
other hand, ii), increased ACh levels in the NA decrease the effects of released 
dopamine. According to pharmacological evidence, it may be also ‘schematically’ 
concluded that ACh effects in NA are mainly mediated by mAChRs whereas in the 
VTA are mediated by nAChRs. These simplistic assumptions have several exceptions, 
depending on dopaminergic system activation and experimental manipulation (basal 
release, acute or chronic stimulation), cholinergic tools used (agonists, antagonists, 
lesions), molecular or behavioural dependent measures.  
Using the AChE-Is as pharmacological tool to increase brain ACh levels, we tried to 
reply to the question: what is the net system effect of increased ACh on nicotine 
addictive behaviour? Is it a VTA-based potentiation or NA-based inhibition? 
Accordingly to general pharmacological principles, AChE-Is effects could be 
reasonably predicted on the basis of a bell-shaped dose-response relationship, where the 
choice of an appropriate dose regimen may avoid dopamine-stimulating doses. 
Secondly, preclinical studies showed different results depending on the type of i), 
symptomatic dimensions, ii), drugs of abuse, iii), or AChE-I tested. 
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Extinction and relapse 
AChE-Is have been pharmacologically characterized using the DD model and tested in 
the S/A paradigm to clarify the role of ACh in mesolimbic dopamingergic pathway. As 
reviewed in the S/A section, nicotine is effective as a reinforcer when different 
schedules of reinforcement are used and different acquisition conditions prevail across 
species and strains. Studies in rats have shown that non-contingent administration of 
nicotine during extinction of nicotine S/A behaviour reinstates responding previously 
reinforced by nicotine (Andreoli et al., 2003; Chiamulera et al., 1996). Exposure to 
drug-paired stimuli also appear effective in reinstating extinguished nicotine-seeking 
behaviour (Dravolina et al., 2007; Lesage et al., 2004; Liu et al., 2006; Liu et al., 2007).  
AChE-Is are used in the clinic for treating cognitive deficits and they act as cognitive 
enhancers. In fact, cholinomimetic drugs, including AChE-Is, significantly improved 
clinical endpoints such as sustained attention, working memory, visual detection, and 
verbal fluency in patients (MacEwan et al., 2001; Kirrane et al., 2001; Lenzi et al., 
2003; Buccafusco, 2004; Chiamulera & Fumagalli, 2007; Chouinard et al., 2007). 
Long-lasting cognitive impairment may act as a determinant factor of relapse to drug 
use (Block et al., 2002). These finding suggested the importance of studying the 
potential therapeutic value of ‘cognitive enhancers’ for prevention of relapse (Vocci et 
al., 2005). According to this rationale, the AChE-I tacrine has been tested on animal 
models that recreate the same clinical conditions of nicotine assumption extinction and 
relapse. In particular, rats have been trained to self-administered nicotine and then 
underwent an extinction session and subsequently to cue- or priming-induced relapse. 
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Tacrine has been chosen as a test compound as it lacks APL properties and had the 
lower degree of generalization with nicotine. With this choice we can avoid a greater 
impact on the activation of nAChRs that would increase the probability of nAChRs 
transition to a desensitised state. Tacrine 0.32 mg/kg administered chronically did not 
exert any effect either on extinction of nicotine S/A behaviour, or on drug cues or 
nicotine priming reinstatement.  
Intraperitoneal administration of donepezil attenuated reinstatement of responding for 
the methamphetamine-associated lever induced by exposure to methamphetamine cues 
or by administration of methamphetamine priming in rats. Furthermore, physostigmine 
reduced heroin S/A to a less extent compared to heroin-seeking behaviour (Zhou et al., 
2007). In fact, while the effect of daily treatment with physostigmine only slightly 
attenuated the acquisition of heroin S/A, this pre-treatment markedly reduced 
subsequent cue-induced reinstatement 14 days after the last administration of 
physostigmine and heroin. A different scenario was obtained when the effects of 
physostigmine were evaluated on heroin-seeking behaviour during cue-induced 
reinstatement or during extinction after intra NA or VTA injection. Physostigmine 
reduced reinstatement but not extinction when injected into NA. On the other hand, 
when injected into the VTA, physostigmine enhanced responding for both reinstatement 
and extinction.  
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Conclusion 
This overall project has a number of limitations. First, administration of non-specific 
cholinomimetic agents, often through a systemic route, made it difficult to assess which 
brain site was targeted by the pharmacological modulation. Second, the use of different 
doses and route of administration did not allow a direct correlation between different 
models. Third, different nicotine doses could have been tested. Moreover, the lack of 
specific neuroanatomical localization of AChE inhibition might be a limitation for 
understanding the mechanism of action of AChE-Is (Takamatsu et al., 2006). 
Based on the results obtained from this research we can conclude that: i), Physostigmine 
and tacrine partially shared a nicotine-like effects, ii) physostigmine and tacrine have no 
effect on nicotine S/A, therefore the net effect of ACh in NA has not been clarified, iii) 
tacrine has no effect on nicotine S/A reinstatement and relapse, excluding that ACh can 
facilitate the learning of extinction behaviour and prevent to cue- or priming-induced 
relapse.  
This data coming evidence on animal models can be integrated with clinical data into a 
more comprehensive picture for the potential use of AChE-Is in nicotine addiction. Few 
studies assessed the efficacy of this class of drugs in subjects with substance abuse and 
dependence problems. The rationale and experimental design for these studies was 
mainly based on the evidence that drug dependent subjects have significant cognitive 
deficits which may act as a determining factor in drug relapse (Block et al., 2002; Vocci 
et al., 2005). However, the results of these clinical studies have not always been 
consistent. For example, donepezil improved cognitive performance for up to three 
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months after discontinuation of methamphetamine in ex-users (Jovanovsky and 
Zakzanis, 2003). In contrast, a recent placebo-controlled study conducted in cocaine-
dependent individuals did not show any significant change in cocaine use during an 8-
week donepezil treatment (Winhusen et al., 2005). Note that in the latter study, subjects 
were currently taking cocaine, whereas subjects were drug abstinent in the former study 
with methamphetamine. In addition, rivastigmine did not change total choices for 
amphetamine and methamphetamine S/A in a study conducted in non-treatment seeking 
methamphetamine users; however, it significantly attenuated methamphetamine-
induced self-reports of “anxiety” and “desire” (De La Garza et al., 2008). Thus, it 
appears that treatment with AChE-Is induced some beneficial effects on cognitive and 
affective dimensions, but not on addiction-related measures (i.e., cocaine use, total 
amphetamine and methamphetamine choices). Similarly, a randomized placebo-
controlled study on prevention of relapse was conducted in recently detoxified 
alcoholics but it did not show a significant difference in cessation rates between placebo 
and a 24-week galantamine treatment group (Mann et al., 2006; Diehl et al., 2006). 
Interestingly, daily alcohol consumption and smoking behaviour (i.e. number of smoked 
cigarette per day and number of smoking days) was significantly reduced. This specific 
effect of galantamine on drug-taking behaviour, but not on prevention of relapse, 
suggest a possible therapeutic effect on psychological dimensions that control drug 
reinforcement but not drug-seeking relapse. To date, the clinical data supporting the 
therapeutic value of AChE-Is for the treatment of drug addiction are not consistent. It is 
possible that such inconsistency may depend on several factors including the different 
classes of drugs of abuse and types and severity of drug addiction symptoms, the 
74 
 
different types and dimensions of clinical endpoints, and the different types and dosing 
regimen of AChE-Is tested.  
Considering that clinical data coming from large clinical trials are fragmented and that 
pre-clinical data are inconsistent, the use of human laboratory analogues of smoking 
behaviour can provide an efficient, cost-effective mechanistic evaluation of a medical 
signal on smoking behaviour. There has been much discussion among the scientific 
community about the need to develop human laboratory models to provide a translation 
between pre-clinical studies and more costly clinical trials. A number of available 
human laboratory models have been designed to investigate the various aspects of 
smoking behaviour and nicotine-dependence phenomena including DD, nicotine 
reinforcement and tolerance and S/A behaviour (see Lerman et al., 2007 and McKee, 
2009 for review). 
In conclusion, testing potential medicinal effects of AChE-Is in animals models of 
nicotine addiction has some limitations but has the potential to indicate some predictive 
elements. The translation of this knowledge to the human laboratory models can clarify 
the real effect of AChE-Is in treating nicotine addiction. 
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